The evolving role of androgen deprivation therapy in the management of prostate cancer

Minerva Urologica e Nefrologica

Volumn 55, Issue 4, 2003, Pages 219-238

  Cooperberg, M R ^a   Small, E J ^a   D'Amico, A ^b   Carroll, P R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgens; Antagonists; Prostatic neoplasms, diagnosis; Prostatic neoplasms, therapy

Indexed keywords

ABARELIX; ADRENAL ANDROGEN SUPPRESSANT; ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; AROMATASE INHIBITOR; BICALUTAMIDE; BUSERELIN; CETRORELIX; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ERYTHROPOIETIN; ESTROGEN; FLUTAMIDE; FOSFESTROL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MEGESTROL ACETATE; NILUTAMIDE; PC SPES; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ALCOHOL INTOLERANCE; ALGORITHM; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BEAM THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHILL; CLINICAL PROTOCOL; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; DEPRESSION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; EDEMA; FATIGUE; FLUSHING; FRACTURE; GYNECOMASTIA; HEALTH CARE COST; HIGH RISK PATIENT; HOT FLUSH; HUMAN; IMPOTENCE; INTERSTITIAL PNEUMONIA; LIBIDO DISORDER; LIVER TOXICITY; MALE; METASTASIS; MONOTHERAPY; MUSCLE MASS; NAUSEA; NIGHT BLINDNESS; NIPPLE; NIPPLE TENDERNESS; ORCHIECTOMY; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT SELECTION; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOPHLEBITIS; WEIGHT GAIN;

ALGORITHMS; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 1542378354     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Huggins C, Hodges R. Studies on prostate cancer: 1. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
3. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53.
4. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565-70.
5. Schellhammer P. Combined androgen blockade for the treatment of metastatic carcinoma of the prostate. Urology 1996;47:622-8.
6. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154-79.
7. Denis LJ, Carneiro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993;42:119-30.
8. Chon JK, Jacobs SC, Naslund MJ. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J Urol 2000;164:735-7.
9. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-7.
10. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for prostate cancer. J Clin Oncol 2001;19:72-80.
11. Zhang XZ, Donovan MP, Williams BT, Mohler JL. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer. Urology 1996;47:402-4.
12. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1992;1:323-9.
13. Byar D. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126-30.
14. Citrin D, Kies MS. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Cancer 1985;56:457-60.
15. Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000;55:328-33.
16. Ockrim JL, Lalani E, Laniado ME, Carter SS, Abel PD. Transdermal estrogen therapy for advanced prostate cancer-forward to the past?. J Urol 2003;169:1735-7.
17. Linde R, Doelle CG, Alexander N, Kirchner F, Vall W, Rivier J et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med 1981;305:663-7.
18. Silver RI, Straus FH, Vogelzang NJ, Kellman H, Chodak GW. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma. Urology 1991;37:17-21.
19. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 1995;46:220-6.
20. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566-77.
21. Agency for Health Care Policy and Research. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. Evidence Report/Technology Assessment: Number 4, January 1999. http:/www.ahrq.gov/clinic/epcsums/prossumm.htm
22. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997;50:330-6.
23. de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000;164:1229-34.
24. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18:3595-603.
25. Decensi A, Boccardo F, Guarneri D, Positano N, Paoletti MC, Castantini M et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991;146:377-81.
26. Kaisary A. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate 1994;5:27-33.
27. Burton S, Trachtenberg J. Effectiveness of antiandrogen in the rat. J Urol 1986;136:932-5.
28. Wysowski D, Fourcroy D. Flutamide-hepatotoxicity. J Urol 1996;155:209-12.
29. Boccardo F, Decensi AU, Guarneri D, Martorana G, Fioretto L, Minu E et al. Anandron (RU23908) in metastatic prostate cancer: preliminary results of a multicentre Italian study. Cancer Detect Prev 1991;15:501-3.
30. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T et al. A randomised comparison of '-Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-56.
31. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17:2027-38.
32. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168:429-35.
33. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982;5:267-75.
34. Crawford ED, Eisenberger M, McLeod DG, Spaulding JT, Benson R, Dorr FA et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24. Erratum in: N Engl J Med 1989;321:1420.
35. Crawford ED, Eisenberger M, McLeod DG, Spaulding JT, Benson R, Dorr FA et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24. Erratum in: N Engl J Med 1989;321:1420.
36. Suciu S, Sylvester R, Iversen P, Christensen I, Denis L. Comparability of prostate trials. Cancer 1993;72:3841-6.
37. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
38. Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisen-berger M, Veith RW et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998;90:1537-44.
39. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;(2):CD001526.
40. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
41. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-91.
42. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491-7.
43. Presti JC Jr, Fair WR, Andriole G, Sogani PC, Seidmon EJ, Ferguson D et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148:1201-4.
44. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995;154:1642-5; discussion 1645-6.
45. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996;48:901-5.
46. Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997;49:913-20.
47. Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 1999;40:105-14.
48. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
49. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001;6:177-82.
50. Higano C, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer. Urology 1996;48:800-4.
51. Higano C, Stephens C, Nelson P. Prospective serial measurements of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen suppression. Proc Am Soc Clin Oncol 1999;18:314A.
52. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998;51:137-44.
53. Horwich A, Huddart R, Gadd J. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998;81:96-9.
54. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35 Suppl 1:27-31.
55. Strum S, McDermed J, Madsen L, Scholz M. Intermittent androgen deprivation (IAD) with finasteride (F) given during the induction and maintenance periods results in prolonged time off IAD in patients with localized prostate cancer (LPC). Proc Am Soc Clin Oncol 1999;18:353A.
56. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149:607-9.
57. Small E, Carroll P. Prostate specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994;43:408-10.
58. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995;153:1946-7.
59. Bissade N, Kaczmarek A. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 1995;153:1944-5.
60. Small E, Schellhammer P, Venner P, Haas G, Nich P, Seabaug DR et al. A double-blind assessment of antiandrogen withdrawal from casodex or eulexin therapy while continuing luteinizing hormone releasing hormone analogue (LHRH-a) therapy for patients with stage D2 prostate cancer. Proc ASCO 1996;15:255.
61. Iversen P, Rose C, Stage JG, Iversen HG, Hansen RI, Hvidt V et al. LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy: a phase II study. Scand J Urol Nephrol 1989;23:177-83.
62. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995;46:849-55.
63. Ornstein DK, Smith DS, Andriole GL. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 1998;52:1094-7.
64. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001;58:53-8.
65. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995;154:448-53.
66. Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000;88:825-34.
67. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hat-field AK, Nelimark RA et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-52.
68. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997;15:2928-38.
69. Figg WD, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz A et al. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. Acta Oncol 1996;35:763-5.
70. Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A et al. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res 1998;4:37-44.
71. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997;80:1755-9.
72. Harris KA, Small EJ, Frohlich MW, Bok R, Randall M, Kakefuda M. Prospective trial of low dose ketoconazole (LDK) therapy in patients (Pts) with androgen-independent prostate cancer (APIC). Proc ASCO 2001;20:2419.
73. Millikan R, Baez L, Banerjee T, Wade J, Edwards K, Winn R et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxombicin in androgen independent prostate cancer. Urol Oncol 2001;6:111-5.
74. Small EJ, Halabi S, Picus J, Chen Y, Vogelzang NJ. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc ASCO 2001;20:695.
75. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257-60.
76. Droz JP, Kattan J, Bonnay M, Chraibi Y, Bekradda M, Culine S. High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer. Cancer 1993;71:1123-30.
77. Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001;57:122-6.
78. Small EJ, Kantoff P, Weinberg VK, Nguyen S, Smith M, Bubley GJ et al. A prospective multicenter randomized trial of the herbal supplement, PC-SPES vs diethylstilbestrol (DES) in patients with advanced, androgen independent prostate cancer (AiPCa). Proc ASCO 2002;21:709.
79. Veldscholte J, Ris-Stalpers C, Kuiper GCJM, Jenster G, Berrevoets C, Claassen E et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-40.
80. Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 2001;92:2095-101.
81. Labrie F, Cusan L, Gomez JL, Belanger A, Candas B. Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol 1999;3:217-26.
82. Akaza H, Homma Y, Okada K, Yokoyama M, Moriyama N, Usami M et al. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group. Jpn J Clin Oncol 2000;30:131-6.
83. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002;60:201-8.
84. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DJ et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002;167:112-6.
85. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002;90:561-6.
86. Gleave ME, Goldenberg SL, Chin JL, Warner J, Sadelain M, Klotz L et al. Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 2003;169:179S.
87. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284:1280-3.
88. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-9.
89. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-99.
90. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000;18:1187-92.
91. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50:1235-42.
92. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
93. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21.
94. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
95. Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002;54:1302-10.
96. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:947-56.
97. Hanks GE, Lu JD, Machtay M, Venkatesan VM, Pin-over WH, Byhardt RW et al. RTOG Protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2000;48:112S.
98. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904-11.
99. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, Phase II Southwest Oncology Group Study 9109. J Urol 2002;168:2016-9.
100. Albertsen PC. The prostate cancer conundrum. J Natl Cancer Inst 2003;95:930-1.
101. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001;58:94-100.
102. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20:557-66.
103. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162:98-102.
104. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25.
105. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
106. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12.